Optimal cessation period of anti-HBV therapy to block mother-to-child transmission
10.3760/cma.j.issn.1007-3418.2019.02.004
- VernacularTitle: 以母婴阻断为目的的抗乙型肝炎病毒药物治疗的停药时间
- Author:
Mao GUO
1
;
Wenqiang LUO
;
Dazhi ZHANG
Author Information
1. Department of Infectious Diseases, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Pregnant;
Mother-to-child transmission;
Antiviral treatment;
Postpartum withdrawal
- From:
Chinese Journal of Hepatology
2019;27(2):92-96
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) carrier woman of childbearing age with high viral load is an important source of vertical transmission of hepatitis b virus from mother-to-child in China. Routine blockade with immunoglobulin combined with hepatitis B vaccine is used for neonates born to pregnant women with high viral load of hepatitis B virus, but in some cases, immunoprophylaxis fails. The main application of antiviral drugs in pregnancy is to reduce the serum viral load, thereby significantly improve the blocking rate of vertical transmission between mother and infant. Current evidence suggested that if the maternal age is less than 30 years old, with no obvious liver fibrosis or cirrhosis and there is no increase in ALT level >2ULN( upper limit of normal) during the treatment, the treatment with antiviral drugs can be stopped after delivery immediately. Additionally, ALT level should be examined at 4, 12 and 24 weeks after stopping the drug. Antiviral therapy for the occurrence of hepatitis attack should be given if criteria for HBV treatment are met.
